BTK and glioblastoma: Collectively, these findings indicated that the novel BTK inhibitors SPA8007 and SPA8009 induce greater cell death in GBM TSs than the other three inhibitors and offers a favorable balance of potency and selectivity for therapeutic application than ibrutinib.